(INFU) InfuSystems Holdings - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45685K1025
INFU: Infusion Pumps, Medical Equipment, Supplies, Services
InfuSystem Holdings, Inc. specializes in providing comprehensive infusion solutions, including ambulatory infusion pumps and associated disposable supply kits, primarily to oncology and infusion clinics across the United States and Canada. The company operates through two distinct segments: Patient Services and Device Solutions. Its product portfolio caters to the treatment of various cancers, including colorectal, breast, and lung cancers, as well as pain management and other chronic conditions. Beyond equipment provision, InfuSystem offers biomedical services such as recertification, maintenance, and repair, ensuring compliance with regulatory standards. Additionally, the company provides customer support through local representatives and operates service centers for equipment maintenance. Incorporated in 2005, InfuSystem is headquartered in Rochester Hills, Michigan.
InfuSystems services extend to selling, renting, and leasing new and pre-owned medical equipment, including pole-mounted and ambulatory infusion pumps. The company also distributes treatment-related consumables, enhancing its role as a one-stop solution for healthcare providers. Its customer base includes hospitals, home care providers, skilled nursing facilities, and pain centers, underscoring its broad impact on healthcare delivery. By focusing on both patient services and device solutions, InfuSystem supports the continuum of care in oncology and beyond.
3-Month Forecast: - Technical Outlook: INFUs price is below its SMA20 and SMA50, suggesting potential bearish momentum. The stock may face resistance at $8.01 (SMA20) and $8.09 (SMA50). Support is anticipated near $7.30 (SMA200). With an ATR of 0.35, moderate volatility is expected. - Fundamental Outlook: The high P/E ratio of 116 indicates a premium valuation, while a P/B ratio of 3.11 suggests the stock is pricey relative to book value. A P/S ratio of 1.30 reflects moderate revenue valuation. The low RoE of 2.67% may signal underperformance in profitability. Overall, the forecast leans neutral to slightly bearish, with potential price stabilization near key moving averages.Additional Sources for INFU Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
INFU Stock Overview
Market Cap in USD | 117m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2007-12-27 |
INFU Stock Ratings
Growth 5y | -23.3% |
Fundamental | 21.6% |
Dividend | 0.0% |
Rel. Strength Industry | -39 |
Analysts | 5/5 |
Fair Price Momentum | 4.55 USD |
Fair Price DCF | 5.35 USD |
INFU Dividends
No Dividends PaidINFU Growth Ratios
Growth Correlation 3m | -67.4% |
Growth Correlation 12m | 9.1% |
Growth Correlation 5y | -72.3% |
CAGR 5y | -1.54% |
CAGR/Max DD 5y | -0.02 |
Sharpe Ratio 12m | -1.44 |
Alpha | -56.13 |
Beta | 2.07 |
Volatility | 58.63% |
Current Volume | 115.9k |
Average Volume 20d | 119.1k |
As of March 15, 2025, the stock is trading at USD 5.55 with a total of 115,853 shares traded.
Over the past week, the price has changed by -9.17%, over one month by -31.65%, over three months by -37.36% and over the past year by -38.47%.
Neither. Based on ValueRay Fundamental Analyses, InfuSystems Holdings is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 21.61 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of INFU as of March 2025 is 4.55. This means that INFU is currently overvalued and has a potential downside of -18.02%.
InfuSystems Holdings has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy INFU.
- Strong Buy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, INFU InfuSystems Holdings will be worth about 5.5 in March 2026. The stock is currently trading at 5.55. This means that the stock has a potential downside of -1.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 14.1 | 154.6% |
Analysts Target Price | 14.1 | 154.6% |
ValueRay Target Price | 5.5 | -1.6% |